A
Antares Therapeutics
Development of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments
About Antares Therapeutics
Antares is a biopharmaceutical entity concentrated on pioneering precision medicine, with a primary emphasis on oncology. The firm's genesis lies in the March 2025 acquisition of Scorpion Therapeutics by Lilly, enabling Antares to leverage Scorpion's established discovery capabilities and validated therapeutic pipeline.
Read full description
Guidance is provided by an executive team with prior experience at Scorpion Therapeutics. Dr. Adam Friedman, with a background as a physician, scientist, and notable experience in oncology, leads as Chief Executive Officer. Amanda Valentino serves as Chief People Officer, contributing over two decades of experience in life sciences talent, human resources, and M&A.
Antares's operational strategy involves pushing scientific boundaries to develop novel therapies. The company's stated mission is to shape the future of precision medicine and deliver treatments that can transform patient lives, particularly within the oncology space. The target market encompasses advanced cancer therapeutics. The business model, characteristic of therapeutics firms, centers on research and development of new drugs, followed by clinical validation and eventual commercialization. The acquisition of its predecessor's assets by Lilly underscores the perceived value of its scientific platform and pipeline.
At a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- Boston, United States
- Employees
- 103
- Open positions
- 5
- Dealroom signal
- 55.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Precision Medicine, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2025 | $177M | $708M | Vida Ventures · Willett Advisors · Tenmile · Vinyanshu Ventures | ↗ |
| CORPORATE SPINOUTOther financing | Jan 2025 | $0 | — | Scorpion Therapeutics | ↗ |
Growth signals
Latest recorded traffic for Antares Therapeutics is 6.9K monthly website visits, up 213.6% over the last three months. Antares Therapeutics's team grew 3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Atlas Venture
BVF Partners
Cormorant Asset Management
Lightspeed Venture Partners
Omega Funds
Vida Ventures
Willett Advisors
Tenmile- VVVinyanshu Ventures
Abingworth
Invus
Series B and later1 investor entered at this stage
Scorpion Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antares Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antares Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.